NEW YORK, December 11 /PRNewswire/ --

- The News Agency's First Syndication Agreement with US Online Video Distribution Platform

RESEARCH TRIANGLE PARK, North Carolina, December 11 /PRNewswire/ --

Quintiles Transnational Corp. today announced the appointment of John Goodacre as Executive Vice President and General Counsel.

Previously Senior Vice President, Global Risk Management and Quality Assurance, Goodacre joined Quintiles in 1998 as Vice President, European Legal Affairs.

IRVINE, California and LONDON, December 11 /PRNewswire/ --

- New Americas Partner Displaces AppStream with Endeavors AppExpress

Endeavors Technologies, the pioneer in application streaming and virtualization technology, and its parent company, Tadpole Technology plc, today announced a partner agreement with Vector Networks, a leading provider of desktop management software for the enterprise. Vector is integrating Endeavors' application streaming and virtualization software as a key component of its IT Asset Management Solution.

CHESHIRE, Connecticut, December 11 /PRNewswire/ --

- Data Presented at the American Society of Hematology (ASH) Annual Meeting

- Publication Number: 840

Soliris(R) (eculizumab) therapy reduced hemolysis, fatigue, thromboses (blood clots) and transfusion requirements in patients with a rare blood disorder called paroxysmal nocturnal hemoglobinuria (PNH), including those who might have been expected to have less severe disease, according to data from an ongoing open-label clinical study presented today at the 49th Annual Meeting of the American Society of Hematology Meeting in Atlanta.

BASEL, Switzerland, December 11 /PRNewswire/ --

- Higher Response Rates Seen in Untreated and Relapsed CLL Patients

For non-US media only

Abstract Number: 626

Abstract Number: 752

Early results from two phase II trials tracking the outcome of patients with chronic lymphocytic leukaemia (CLL) who were treated with the innovative cancer therapy MabThera (rituximab) have revealed very promising results. The study outcomes, presented at the 49th Annual Meeting of the American Society of Hematology in Atlanta, come from the first prospective trials demonstrating the efficacy of MabThera in CLL patients and highlight the impact MabThera is having on CLL, a disease in which there has not been a significant treatment advance in nearly a decade.

JERUSALEM, Israel, December 11 /PRNewswire/ --

- DS Vision 3000 Now Reaches 600m

Minicom Advanced Systems is proud to announce the extended range of its DS Vision 3000. The CATx based distribution system which delivers HD video and stereo-audio content from a player to multiple screens has doubled its scope from 300m (1000ft) to 600m (2000ft).

According to Eran Kessel, Vice President for Marketing at Minicom, "The increased range of the DS Vision 3000 makes it an even more powerful solution to any digital signage solution. To be able to send high quality images over this distance and price-performance is something that no-one else has been able to achieve."